172 related articles for article (PubMed ID: 38173005)
1. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
López-Velazco JI; Manzano S; Otaño M; Elorriaga K; Bultó N; Herrero J; Lahuerta A; Segur V; Álvarez-López I; Caffarel MM; Urruticoechea A
Breast Cancer Res; 2024 Jan; 26(1):3. PubMed ID: 38173005
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer.
Ragusi MA; Winter-Warnars GA; Wesseling J; Linn SC; Beets-Tan RG; van der Velden BH; Elias SG; Gilhuijs KG; Loo CE
Br J Radiol; 2021 Jul; 94(1123):20201125. PubMed ID: 34142870
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.
da Silva LR; de Andrade CA; Brenelli F; Ramalho S; Reinert T; de Souza ABA; da Silva AER; de Paula Leite Kraft MB; de Vasconcelos VCA; Frasson AL; Torresan RZ; Cabello C; Ellis MJ; Zeferino LC
Breast Cancer Res Treat; 2021 Apr; 186(3):753-760. PubMed ID: 33543355
[TBL] [Abstract][Full Text] [Related]
4. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
5. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
6. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
van Olmen JP; Jacobs CF; Bartels SAL; Loo CE; Sanders J; Vrancken Peeters MTFD; Drukker CA; van Duijnhoven FH; Kok M
Breast; 2024 Jun; 75():103726. PubMed ID: 38599047
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study.
Wang X; Fan Z; Wang X; He Y; Liu Y; Wang X; Zhang B; Jiang Z; Wang T; Yu Z; Wang F; Liu Y; Li Y; Zhang J; Luo B; Jiang H; Wang T; Xie Y; Li J; Ouyang T
Breast Cancer Res Treat; 2022 Oct; 195(3):301-310. PubMed ID: 35917052
[TBL] [Abstract][Full Text] [Related]
8. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
9. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Martins-Branco D; Nader-Marta G; Molinelli C; Ameye L; Paesmans M; Ignatiadis M; Aftimos P; Salgado R; de Azambuja E
Eur J Cancer; 2023 Nov; 194():113358. PubMed ID: 37857118
[TBL] [Abstract][Full Text] [Related]
11. The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
Oner G; Broeckx G; Van Berckelaer C; Zwaenepoel K; Altintas S; Canturk Z; Tjalma W; Berneman Z; Peeters M; Pauwels P; van Dam PA
Cancer Med; 2023 Sep; 12(17):17901-17913. PubMed ID: 37553911
[TBL] [Abstract][Full Text] [Related]
12. Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.
Ragusi MAA; Loo CE; van der Velden BHM; Wesseling J; Linn SC; Beets-Tan RG; Elias SG; Gilhuijs KGA
Eur Radiol; 2020 Dec; 30(12):6740-6748. PubMed ID: 32691100
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Yeo B; Dowsett M
Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
Madigan LI; Dinh P; Graham JD
Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study.
Martí C; Yébenes L; Oliver JM; Moreno E; Frías L; Berjón A; Loayza A; Meléndez M; Roca MJ; Córdoba V; Hardisson D; Rodríguez MÁ; Sánchez-Méndez JI
Curr Oncol; 2022 Mar; 29(4):2199-2210. PubMed ID: 35448153
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments.
Reis J; Lindstrøm JC; Boavida J; Gjesdal KI; Park D; Bahrami N; Seyedzadeh M; Melles WA; Sauer T; Geisler J; Geitung JT
Breast Cancer Res Treat; 2020 Nov; 184(2):407-420. PubMed ID: 32789592
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
